Wyeth (Collegeville, Pa) recently announced FDA approval for Protonix I.V. (pantoprazole sodium) for Injection, for intravenous administration over a period of at least 2 minutes, in addition to its current 15-minute infusion regimen. Protonix I.V. is indicated for short-term treatment (7 to 10 days) in patients having gastroesophageal reflux disease with a history of erosive esophagitis. It is an alternative to oral therapy for patients who are unable to continue taking Protonix Delayed-Release Tablets. Protonix is the first and only proton pump inhibitor in the United States to be offered in both oral and IV formulations. Hospital personnel will be able to administer treatment with Protonix I.V. more quickly as a result of the decrease in both preparation time and infusion time. For more information, visit www.wyeth.com, or call 800-395-9938.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs